| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $969.0M | -6.2% | +6.8% |
| Cost of Revenue | $659.0M | -1.8% | +14.6% |
| R&D Expense | $26.0M | +13.0% | +23.8% |
| SG&A Expense | $113.0M | +7.6% | +5.6% |
| Pre-tax Income | $173.0M | -13.1% | -12.2% |
| Income Tax | $182.0M | +80.2% | +271.4% |
| Net Income | -$35.0M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $417.0M | — | — |
| Accounts Receivable | $635.0M | — | — |
| Inventory | $732.0M | — | — |
| Current Assets | $1.88B | — | — |
| Total Assets | $5.25B | — | — |
| Current Liabilities | $1.23B | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $289.0M | — | — |
| Capital Expenditures | $248.0M | — | — |
| Investing Cash Flow | -$228.0M | — | — |
| Financing Cash Flow | -$328.0M | — | — |
| Free Cash Flow | $41.0M | — | — |
| -136.1% |
| -123.0% |
| — |
| Total Liabilities | $2.07B | — | — |
| Stockholders' Equity | $3.23B | -7.1% | +0.3% |